Skip to main content

Table 1 Study population characteristics

From: Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation

  Total (n = 951) All-Vac group (n = 728) Vac-1 group (n = 346) Vac-2 group (n = 382) Control group (n = 223) Pv
Age (years) 68.3 (59.0-75.4) 69.2 (61.1–76.2) 68.3 (57.6–76.5) 70.0 (62.2–76.0) 65.0 (54.1–71.9) <0.01 a,b
Female 544 (57.2%) 413 (56.7%) 197 (56.9%) 216 (56.5%) 131 (58.7%) 0.86
Lymphoma 163 (17.1%) 113 (15.5%) 53 (15.3%) 60 (15.7%) 50 (22.4%) 0.06
Lung malignancy 150 (15.8%) 124 (17.0%) 63 (18.2%) 61 (16.0%) 26 (11.7%) 0.11
Breast malignancy 143 (15.0%) 113 (15.5%) 54 (15.6%) 59 (15.4%) 30 (13.5%) 0.75
Colorectal/other lower GI malignancy 110 (11.6%) 83 (11.4%) 43 (12.4%) 40 (10.5%) 27 (12.1%) 0.68
Gynecological malignancy 74 (7.8%) 51 (7.0%) 20 (5.8%) 31 (8.1%) 23 (10.3%) 0.14
Genitourinary malignancy 50 (5.3%) 40 (5.5%) 18 (5.2%) 22 (5.8%) 10 (4.5%) 0.79
Pancreatic malignancy 44 (4.6%) 36 (4.9%) 18 (5.2%) 18 (4.7%) 8 (3.6%) 0.67
Head and neck malignancy 42 (4.4%) 35 (4.8%) 18 (5.2%) 17 (4.5%) 7 (3.1%) 0.50
Melanoma/other skin malignancy 41 (4.3%) 32 (4.4%) 16 (4.6%) 16 (4.2%) 9 (4.0%) 0.93
Sarcoma (including GIST) 38 (4.0%) 27 (3.7%) 11 (3.2%) 16 (4.2%) 11 (4.9%) 0.56
Myeloma 34 (3.6%) 26 (3.6%) 10 (2.9%) 16 (4.2%) 8 (3.6%) 0.64
Upper GI malignancy 33 (3.5%) 27 (3.7%) 13 (3.8%) 14 (3.7%) 6 (2.7%) 0.77
Other malignancies 17 (1.8%) 12 (1.6%) 6 (1.7%) 6 (1.6%) 5 (2.2%) 0.83
Non-oncological conditions 12 (1.3%) 9 (1.2%) 3 (0.9%) 6 (1.6%) 3 (1.3%) 0.69
Staging 213 (22.4%) 166 (22.8%) 89 (25.7%) 77 (20.2%) 47 (21.1%) 0.17
Monitor response to therapy 473 (49.7%) 335 (46.0%) 157 (45.4%) 178 (46.6%) 138 (61.9%) <0.01 a,b
 Chemotherapy 283 (29.8%) 191 (26.2%) 90 (26.0%) 101 (26.4%) 92 (41.3%) <0.01 a,b
 Radiotherapy 64 (6.7%) 42 (5.8%) 24 (6.9%) 18 (4.7%) 22 (9.9%) 0.05 b
 Biologic therapy 193 (20.3%) 141 (19.4%) 62 (17.9%) 79 (20.7%) 52 (23.3%) 0.29
 Immunotherapy 73 (7.7%) 55 (7.6%) 27 (7.8%) 28 (7.3%) 18 (8.1%) 0.94
Recurrent malignancy 105 (11.0%) 89 (12.2%) 42 (12.1%) 47 (12.3%) 16 (7.2%) 0.11
Follow-up with NED 148 (15.6%) 129 (17.7%) 55 (15.9%) 74 (19.4%) 19 (8.5%) <0.01 a,b
Non-oncological indication 12 (1.3%) 9 (1.2%) 3 (0.9%) 6 (1.6%) 3 (1.3%) 0.69
  1. Categorical variables are reported as frequency and percentage. Continuous variables are reported as median and IQR
  2. aa significant difference was found between Vac-1 and control groups
  3. ba significant difference was found between Vac-2 and control groups
  4. GI, gastrointestinal; GIST, gastrointestinal stromal tumor; NED, no evidence of disease